Assembly Biosciences To Highlight Pipeline Progress In HBV And HDV At The 2023 International HBV Meeting
Portfolio Pulse from Happy Mohamed
Assembly Biosciences, Inc. (NASDAQ:ASMB) will present new preclinical data from its hepatitis B and D virus (HBV/HDV) pipeline programs at the 2023 International HBV Meeting. The company will highlight progress in its HBV/HDV oral entry inhibitor program and its interferon-alpha receptor agonist program. The data for ABI-4334, Assembly Bio's capsid assembly modulator, supports its potential to prevent HBV DNA integration, a process linked to liver cancer in HBV patients. Assembly Bio anticipates nominating a development candidate from the HBV/HDV entry inhibitor program in 2023.
September 19, 2023 | 8:10 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Assembly Biosciences will present new preclinical data from its HBV/HDV programs, which could potentially lead to a new development candidate. This could positively impact the company's stock in the short term.
The announcement of new preclinical data and the potential nomination of a new development candidate could increase investor confidence in Assembly Biosciences, potentially leading to a rise in the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100